CN103513038B - 半乳糖凝集素3检测试剂盒及制备方法 - Google Patents
半乳糖凝集素3检测试剂盒及制备方法 Download PDFInfo
- Publication number
- CN103513038B CN103513038B CN201310181883.6A CN201310181883A CN103513038B CN 103513038 B CN103513038 B CN 103513038B CN 201310181883 A CN201310181883 A CN 201310181883A CN 103513038 B CN103513038 B CN 103513038B
- Authority
- CN
- China
- Prior art keywords
- solution
- galectin
- reagent
- latex particle
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000000802 Galectin 3 Human genes 0.000 title claims abstract description 87
- 108010001517 Galectin 3 Proteins 0.000 title claims abstract description 87
- 238000001514 detection method Methods 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000004816 latex Substances 0.000 claims abstract description 130
- 229920000126 latex Polymers 0.000 claims abstract description 130
- 239000002245 particle Substances 0.000 claims abstract description 127
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 96
- 238000006243 chemical reaction Methods 0.000 claims description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 239000007987 MES buffer Substances 0.000 claims description 41
- 239000012153 distilled water Substances 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- 238000013016 damping Methods 0.000 claims description 27
- 239000012530 fluid Substances 0.000 claims description 27
- 230000009514 concussion Effects 0.000 claims description 25
- 239000006228 supernatant Substances 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- 238000004321 preservation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 239000004793 Polystyrene Substances 0.000 claims description 9
- 229920002223 polystyrene Polymers 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 8
- 239000000375 suspending agent Substances 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000002981 blocking agent Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 238000010382 chemical cross-linking Methods 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 17
- 230000002421 anti-septic effect Effects 0.000 description 12
- 239000006177 biological buffer Substances 0.000 description 11
- 150000001718 carbodiimides Chemical class 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000003352 sequestering agent Substances 0.000 description 7
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000007563 Galectins Human genes 0.000 description 5
- 108010046569 Galectins Proteins 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- -1 beta galactose glycosides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102000000805 Galectin 4 Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010065785 galectin 5 Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310181883.6A CN103513038B (zh) | 2013-05-16 | 2013-05-16 | 半乳糖凝集素3检测试剂盒及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310181883.6A CN103513038B (zh) | 2013-05-16 | 2013-05-16 | 半乳糖凝集素3检测试剂盒及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103513038A CN103513038A (zh) | 2014-01-15 |
CN103513038B true CN103513038B (zh) | 2015-06-10 |
Family
ID=49896087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310181883.6A Active CN103513038B (zh) | 2013-05-16 | 2013-05-16 | 半乳糖凝集素3检测试剂盒及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103513038B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103954766B (zh) * | 2014-01-24 | 2015-07-15 | 武汉生之源生物科技有限公司 | 转铁蛋白受体检测试剂盒及制备方法 |
CN104155456B (zh) * | 2014-08-22 | 2016-11-02 | 山东博科生物产业有限公司 | 一种稳定性强的肌钙蛋白检测试剂盒 |
CN104897904A (zh) * | 2015-05-29 | 2015-09-09 | 中生北控生物科技股份有限公司 | 一种羧基微球标记蛋白的方法 |
CN107383192B (zh) * | 2017-07-19 | 2018-08-24 | 深圳市倍诺博生物科技有限公司 | 半乳糖凝集素-3检测试剂盒 |
CN107490675B (zh) * | 2017-08-10 | 2019-02-12 | 迈克生物股份有限公司 | 一种免疫比浊试剂盒及检测方法 |
CN107543931B (zh) * | 2017-09-12 | 2020-02-21 | 四川新健康成生物股份有限公司 | 基于胶乳增强免疫比浊法检测TnI的试剂盒及其制备方法 |
CN111505304A (zh) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | 一种化学发光法检测半乳糖凝集素-3的试剂盒及使用方法 |
CN115746134A (zh) * | 2021-10-15 | 2023-03-07 | 深圳市睿盟创新生物科技有限公司 | 半乳糖凝集素-3的免疫测定 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106152A1 (en) * | 2011-02-03 | 2012-08-09 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
CN102645540A (zh) * | 2012-04-01 | 2012-08-22 | 安徽四正医药科技有限公司 | 一种用于诊断肝纤维化和早期肝硬化的血液标志物 |
CN103048464A (zh) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110194996A1 (en) * | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Transport container for stabilized liquid samples |
-
2013
- 2013-05-16 CN CN201310181883.6A patent/CN103513038B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106152A1 (en) * | 2011-02-03 | 2012-08-09 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
CN102645540A (zh) * | 2012-04-01 | 2012-08-22 | 安徽四正医药科技有限公司 | 一种用于诊断肝纤维化和早期肝硬化的血液标志物 |
CN103048464A (zh) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103513038A (zh) | 2014-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103513038B (zh) | 半乳糖凝集素3检测试剂盒及制备方法 | |
CN102175871B (zh) | 双胶乳法测定血清或尿液中游离轻链的液体双试剂试剂盒 | |
CN106814193B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒 | |
CN104237522A (zh) | 脂联素含量检测试剂盒及其制备方法 | |
CN107402308A (zh) | Il‑6定量检测试剂盒及其制备方法 | |
CN104198723A (zh) | 一种基于氨基酸间臂的ngal快速检测试剂盒 | |
CN102998468A (zh) | 25-羟基维生素d3检测试剂盒及其制备方法和应用 | |
CN106353507A (zh) | 一种检测血清淀粉样蛋白的试剂盒及其用途 | |
CN109725160B (zh) | 一种降钙素原(pct)检测试剂盒 | |
CN109374902A (zh) | 一种定量检测IgG4的乳胶增强免疫比浊试剂盒及其制备方法 | |
CN107860929A (zh) | 一种血清淀粉样蛋白a的免疫比浊检测试剂和方法 | |
CN104569434A (zh) | 高尔基体蛋白gp73乳胶增强免疫比浊检测试剂盒及其制备方法 | |
CN109307765A (zh) | 胃蛋白酶原ⅱ检测试剂盒 | |
WO2021088730A1 (zh) | 游离前列腺特异性抗原检测试剂盒及其制备方法 | |
CN109212192A (zh) | 用于原发性肝癌早期诊断的gp73检测试剂盒 | |
CN103323596A (zh) | 髓过氧化物酶含量检测试剂盒及其制备方法 | |
CN102809654A (zh) | 一种双粒子复合的c-反应蛋白检测试剂盒 | |
CN104356226B (zh) | 一种检测血浆免疫标志物‑vegfr1自身抗体的抗原多肽及应用 | |
CN105606822A (zh) | β2-微球蛋白检测试剂盒 | |
CN108570104A (zh) | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 | |
CN112858698B (zh) | 一种d-二聚体胶乳增强免疫比浊试剂盒及其制备方法 | |
CN111912990B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN105988003B (zh) | 一种全程c反应蛋白测定试剂盒及其应用 | |
CN111505304A (zh) | 一种化学发光法检测半乳糖凝集素-3的试剂盒及使用方法 | |
CN106290902A (zh) | 一种血清淀粉样蛋白a1的胶体金检测卡及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 430223 B11 building, No. 818, hi tech medical center, hi tech Avenue, East Lake Development Zone, Wuhan, Hubei, 2 Patentee after: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Address before: 430223 Hubei city of Wuhan province East Lake Development Zone Road, University of Wuhan University of science and Technology Park building four floor Patentee before: Wuhan Life Origin Biotech Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection kit for galectin-3 and preparation method thereof Effective date of registration: 20180612 Granted publication date: 20150610 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190620 Granted publication date: 20150610 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: 2018420000024 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection kit for galectin-3 and preparation method thereof Effective date of registration: 20190813 Granted publication date: 20150610 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK CO., LTD. Registration number: Y2019420000004 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201223 Granted publication date: 20150610 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. Registration number: Y2019420000004 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: 430000 1 / F, 2 / F and 3 / F, B11, hi tech medical device Park, 818 Gaoxin Avenue, Donghu Development Zone, Wuhan, Hubei Province Patentee after: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. Address before: 2 / F, B11, Gaoke medical instrument Park, 818 Gaoxin Avenue, Donghu Development Zone, Wuhan, Hubei 430223 Patentee before: WUHAN LIFE ORIGIN BIOTECH JOINT STOCK Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |